.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,977,045

« Back to Dashboard

Claims for Patent: 7,977,045

Title:Aqueous-based pharmaceutical composition
Abstract: An aqueous pharmaceutical composition which is capable of being sprayed into the nasal cavity of an individual and which comprises: (A) a pharmaceutically effective amount of solid particles of medicament which is effective in treating a bodily condition by virtue of its being present on the mucosal surfaces of the nasal cavity; and (B) a suspending agent in an amount effective to maintain said particles dispersed uniformly in the composition and to impart to the composition the following thixotropic properties: (i) the viscosity of the position in unsheared form is relatively high, with the composition being in gel-like form; (ii) as the composition is subjected to shear (shaken) in preparation for spraying, the viscosity of the composition becomes relatively low and such that the composition in the form of a mist flows readily into the nasal passages for deposit on the mucosal surfaces of the nasal cavity; and (D) in deposited form on the mucosal surfaces, the viscosity of the composition is relatively high and such that it resists being cleared from the mucosal surfaces by the inherent mucocillary forces which are present in the nasal cavity, a method of use of the composition and a method for preparation of the composition, including in preferred form the use of anti-inflammatory steroid, for example, triamcinolone acetonide, and an odorless form of the composition.
Inventor(s): Kim; Soo-Il (Maple Glen, PA)
Assignee: Aventis Pharmaceuticals Inc. (Bridgewater, NJ)
Application Number:12/728,984
Patent Claims: 1. A method for applying solid particles of a medicament to the mucosal surfaces of the nasal cavities comprising spraying a dose of an aqueous pharmaceutical composition containing said medicament into each of the nasal cavities, said dose containing a pharmaceutically effective amount of said medicament, said composition including also a suspending agent in an amount which is effective in maintaining said particles dispersed uniformly in the composition and in imparting to the composition a shear viscosity such that pharmaceutically effective amounts of the medicament are deposited on each of the mucosal surfaces of the anterior regions of the nose, the frontal sinus and the maxillary sinuses and on each of the mucosal surfaces which overlie the turbinates covering the conchas and a setting viscosity such that portions of said amounts are retained on each of said mucosal surfaces for at least about an hour, said medicament consisting essentially of triamcinolone acetonide.

2. A method according to claim 1 wherein said dose includes said triamcinolone acetonide in an amount effective to provide relief from allergic rhinitis symptoms.

3. A method according to claim 2 wherein the setting viscosity of the composition is about 50 to about 200 centipoises and the shear viscosity of the composition is about 400 to about 1000 centipoises.

4. A method according to claim 3 wherein said composition is odorless and includes also a quaternary ammonium compound and a chelating agent and wherein said suspending agent consists essentially of a mixture of microcrystalline cellulose and carboxymethylcellulose sodium.

5. A method according to claim 4 wherein said ammonium compound consists essentially of benzalkonium chloride and said chelating agent consists essentially of EDTA.

6. A method according to claim 1 wherein said composition is sprayed by a precompression pump.

7. An aqueous pharmaceutical composition which is capable of being sprayed into the nasal cavity of an individual and which comprises: (A) a pharmaceutically effective amount of solid particles of triamcinolone acetonide which is effective in treating a condition in an individual by virtue of its being present on the mucosal surfaces of the nasal cavity of the individual; and (B) a suspending agent in an amount effective to maintain said particles dispersed uniformly in the composition and to impart to the composition the following properties: (i) the viscosity of the position in unsheared form is relatively high, with the composition being in gel-like form; (ii) as the composition is subjected to shear (shaken) in preparation for spraying, the viscosity of the composition becomes relatively low and such that the composition in the form of a mist flows readily into the nasal passages for deposit on the mucosal surfaces of the nasal cavity; and (D) in deposited form on the mucosal surfaces, the viscosity of the composition is relatively high and such that it resists being cleared from the mucosal surfaces by the inherent mucocillary forces which are present in the nasal cavity.

8. A composition according to claim 7 wherein the relatively low viscosity of the composition is about 50 to about 200 centipoises and the relatively high viscosity of the composition is about 400 to about 1000 centipoises.

9. A composition according to claim 8 which is odorless and which includes a quaternary ammonium compound and a chelating agent.

10. A composition according to claim 9 wherein the quaternary ammonium compound consists essentially of benzalkonium chloride, the chelating agent consists essentially of EDTA and the suspending agent consists of a mixture of microcrystalline cellulose and carboxymethyl cellulose sodium.

11. A composition according to claim 10 wherein the setting viscosity of the composition is about 400 cp to about 800 centipoises and the shear viscosity is about 100 cp to about 200 centipoises.

12. A method for preparing an aqueous pharmaceutical composition comprising triamcinolone acetonide in the form of solid particles, a dispersing agent for wetting said particles, and a suspending agent for maintaining said particles substantially uniformly dispersed in the composition and for imparting to the composition thixotropic properties comprising: (A) forming an aqueous solution of the dispersing agent and combining the solution with the solid particles to form a suspension of the particles; (B) adding the suspending agent to an aqueous acidic solution to form a thixotropic suspension; and (C) combining each of the suspensions by introducing one of the suspensions into the bottom of the other suspension.

13. A method according to claim 12 wherein the suspension of particles is introduced into the bottom of the thixotropic suspension.

14. A method according to claim 13 in which the suspension of particles includes a hydrophilic non-ionic surfactant and a quaternary ammonium anti-microbial agent and in which the thixotropic suspension includes a chelating agent and an anti-osmotic agent.

15. A method according to claim 14 wherein the anti-microbial agent consists essentially of benzalkonium chloride, the chelating agent consists essentially of EDTA and the anti-osmotic agent consists essentially of dextrose.

16. An aqueous pharmaceutical composition which is capable of being sprayed into the nasal cavity of an individual, which has a pH of about 4.8, and which comprises: TABLE-US-00002 COMPONENT Wt. % triamcinolone acetonide, 0.055 micronized topical grade mixture of microcrystalline 2.0 cellulose and carboxymethyl- cellulose sodium Polysorbate 80 surfactant 0.004 disodium ethylenediamine 0.05 tetraacetate benzalkonium chloride 0.03 (BzCl) solution, 50 wt. % of BzCl dextrose (anhydrous) 5.0 purified water 92.86 diluted hydrochloric acid pH, 0.1N NaOH solution about 4.8.

17. An article of manufacture comprising: (A) a thixotropic aqueous pharmaceutical composition which is propellant-free and has a pH of about 4.5 to 7.5, and which comprises (a) triamcinolone acetonide; (b) a mixture of microcrystalline cellulose and carboxymethylcellulose sodium; (c) Polysorbate 80; (d) disodium ethylenediamine tetraacetate; (e) benzalkonium chloride; (f) dextrose; and (g) purified water; (B) a vessel containing the composition; and (C) a precompression pump associated with the vessel and which is capable of spraying a dose of the composition.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc